Although anti-programmed death 1 (PD-1) and anti-PD-L1 agents have shown significant clinical efficacy and lasting responses with minimal side effects 32, 33, many patients with cancer may not benefit from them, or they may not exhibit ideal efficacy 34. Here, CD274 is linked to cancer.